CANA/Met in Non-diabetic Women With PCOS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

July 8, 2021

Study Completion Date

March 8, 2022

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Canagliflozin combined with metformin

"Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS."

DRUG

metformin

Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.

Trial Locations (1)

110004

Shengjing Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

Shengjing Hospital

OTHER

NCT04973891 - CANA/Met in Non-diabetic Women With PCOS | Biotech Hunter | Biotech Hunter